Endonovo Therapeutics Inc (PK:ENDV)

Mar 28, 2024 09:03 am ET
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual...
Mar 04, 2024 09:09 am ET
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical...
Dec 04, 2023 09:15 am ET
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the...
Oct 12, 2023 09:07 am ET
Endonovo's SofPulse® Secures Taiwan FDA Approval
Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of...
Aug 22, 2023 09:07 am ET
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply Schedule (FSS) for SofPulse® Pulsed Electro Magnetic Field (PEMF) medical devices for distribution...
Aug 08, 2023 09:03 am ET
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
Endonovo Therapeutics Inc. (OTCQB: ENDV) -- commercial developer of medical technology-- is proud to announce a series of advancements in the first half of 2023. The Company has made significant strides in multiple areas of sales, marketing,...
Jun 22, 2023 01:02 pm ET
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
FMW Media Works' New to The Street will feature Endonovo Therapeutics, Inc. (OTCQB: ENDV) ($ENDV) on its nationally syndicated and sponsored television program. The series will span six (6) months following Endonovo Therapeutics' business mission...
Jun 07, 2023 09:07 am ET
Endonovo Pending Agreement to Develop Telehealth Division
Endonovo Therapeutics, Inc. (OTCQB: ENDV), an industry leading medical technology company, is working with a prominent developer of telehealth (telemedicine) platforms to establish a new telehealth division for Endonovo. “Endonovo’s...
May 02, 2023 09:03 am ET
Endonovo Launches SofPulse® into the Veterans Administration
Endonovo Therapeutics, Inc. (OTCQB: ENDV) a US-based biotechnology developer, today announced the launch of SofPulse® with Academy Medical, Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller. As was previously...
Apr 25, 2023 09:07 am ET
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment. The Company is actively seeking to...
Apr 13, 2023 09:07 am ET
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial stage developer of non-invasive medical devices, is pleased to announce its partnership with David Irving, former NFL (National Football League) defensive lineman, as brand ambassador for...
Apr 10, 2023 12:01 pm ET
Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
Endonovo Therapeutics Inc (OTCQB: ENDV) -- a pioneer in bioelectronic medical devices -- announced today its partnership with world-renowned musician and philanthropist, Andy Vargas, and his wife, Nicole Vargas, to promote its innovative non-opioid...
Mar 29, 2023 09:07 am ET
Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced a binding Letter of Intent (LOI) to spin off its current medical device division to an entity controlled by Ira Weisberg, who will be the future President and CEO of a newly formed...
Mar 23, 2023 09:03 am ET
Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a medical device company known for its innovative and effective pain management solutions -- announced today that it is entering the final stages of clearance to receive a Taiwan FDA (TFDA) License for...
Mar 15, 2023 09:05 am ET
Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery 
Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced details today of the remarkable experience of one of its Scientific Advisory Board Members, Dr. Gary Berns, while overseeing the rehabilitation treatments of Olympian and Surfing Champion Carlos...
Mar 06, 2023 09:07 am ET
Endonovo Announces Distribution Agreement with Academy Medical
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the signing of a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller Agreement (Agreement or Contract) with Academy Medical, Inc. of West Palm Beach, FL to distribute...
Feb 28, 2023 09:09 am ET
Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a medical device company specializing in pulsed electromagnetic field (PEMF) technology, announced today it will hold a question and answer session for shareholders on March 9, 2023 at 4:30pm EST with Ira...
Jan 31, 2023 09:07 am ET
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the retention of Ocean Tomo, a part of J.S. Held, to conduct a fairness opinion analysis in connection with the proposed spin-off of Endonovo’s medical device assets to a newly formed...
Jan 26, 2023 09:03 am ET
Endonovo Partners with International Distributor for SofPulse® Line
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced a new non-exclusive stocking distributor agreement with Pulse Therapeutics Technology, Inc. (the “Distributor”) to purchase and distribute its SofPulse® medical devices into Mexico and Costa...
Jan 19, 2023 09:05 am ET
New Details on Endonovo’s Spin-Off of SofPulse, Inc.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced today details regarding the planned spin-off of its medical device assets to a newly formed Delaware company, SofPulse, Inc. SofPulse, Inc. Will Operate Independently SofPulse, Inc. will operate...
Jan 09, 2023 09:03 am ET
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced details for its plan to spin off its current medical device division, known as NewCo, as a separate publicly-traded company. Endonovo’s other current division focuses on mergers and...
Jan 03, 2023 09:09 am ET
Endonovo Targets Dept. of Defense, VA & Federal Contracts
Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical device distribution through the U.S. Department of Defense (DoD), Veterans Administration (VA) and...
Dec 19, 2022 09:09 am ET
Endonovo Announces Advancement of International “Go to Market” Initiative
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced an aggressive initiative to introduce and develop the sales and benefits of SofPulse® medical devices into multiple international markets as part of its global “Go to Market” strategy....
Dec 15, 2022 09:07 am ET
Endonovo Announces Plans for Spin-off of Medical IP and Assets
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to affect a spin-off of its medical device assets to a new company (“NewCo”) being formed by its current President and Chief Commercial Officer of its Medical Division, Ira Weisberg....
Dec 13, 2022 09:11 am ET
Endonovo Launches Telehealth Initiative
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options. The Endonovo...
Nov 30, 2022 09:07 am ET
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division. “Ira will be responsible for expanding global sales and marketing operations, including: business development,...
Nov 17, 2022 09:07 am ET
ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. This may include, but is...
Nov 07, 2022 09:07 am ET
Endonovo Therapeutics Issues Corporate Update
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today issued an update regarding recent corporate developments. The Company noted advancement of its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the...
Sep 27, 2022 01:52 pm ET
Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company
Endonovo Therapeutics Inc. (OTCQB: ENDV) and Western Star Concrete LLC, a highly profitable Texas concrete construction company located in the greater Dallas region, today announced the signing of a definitive purchase agreement for Endonovo to...
Jul 28, 2022 09:08 am ET
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were...
Jul 21, 2022 11:30 am ET
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
Endonovo Therapeutics Inc. (OTCQB:ENDV) today released a comparative analysis detailing how its SofPulse® medical device out-performed all pharmaceutical competitors non-opioid alternatives for surgical pain management. Competitive...
Jun 09, 2022 02:02 pm ET
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
Endonovo Therapeutics Inc. (OTCQB:ENDV) today announced a Letter of Intent to purchase a highly-regarded market leading specialty concrete services company located in the Southern U.S. with unaudited 2021revenue of $47.7M and Earnings Before...
Apr 25, 2022 09:08 am ET
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient...
Apr 11, 2022 09:08 am ET
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its SofPulse® devices with its SEC filing of a $5 million Regulation A+ common stock offering currently in...
Mar 01, 2022 09:10 am ET
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
Endonovo Therapeutics Inc. (OTC-ENDV), a developer and distributor of Innovative Medical Devices is pleased to announce that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate “build...
Feb 16, 2022 09:10 am ET
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
Endonovo Therapeutics Inc. (OTC-ENDV) an Innovative Medical Devices developer and distributor is pleased to announce it has filed a Regulation A+ financing for expansion of their operations and has retained Dalmore Group (“Dalmore”), a veteran...
Oct 12, 2021 04:05 pm ET
Endonovo Therapeutics Issues Shareholder Update
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today issued an update to its shareholders regarding recent corporate developments, in particular, with respect to its historical core business as well as the development of...
May 11, 2021 08:00 am ET
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in a Stanford University sponsored Orthopedic Shoulder and Knee Study. The Stanford Orthopedic study...
Oct 08, 2020 08:00 am ET
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today a new marketing and public awareness campaign around their FDA Cleared SofPulse® that has been proven to help the in the response to the opioid epidemic during...
Sep 09, 2020 08:00 am ET
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reducti
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an additional opportunity to view a live webinar presentation ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients...
Aug 20, 2020 02:51 pm ET
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended June 30, 2020. Key Financial Highlights: Operating Results for the Three Months Ended June 30,...
Jul 27, 2020 09:00 am ET
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled ‘The Impact of Pulsed...
Jul 21, 2020 09:00 am ET
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced the Company’s registration statement on Form S-1 relating to its equity credit line with Calvary Fund I LP has been ordered effective by the Securities and...
Jun 15, 2020 08:00 am ET
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter ended March 31, 2020. Company improved financial and operating results are reflected in every major...
Jun 01, 2020 10:00 am ET
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the signing of a Sales and Strategic Partnership Agreement with Evermed Medical Enterprise Ltd., a leading medical device distributor in Taiwan, ROC (Republic...
May 26, 2020 08:18 am ET
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") announced today it has executed a new Equity Line Purchase Agreement with Cavalry Fund I, LP (“Cavalry”) to sell up to $10 Million in common stock to Cavalry over a term of 24...
May 04, 2020 08:15 am ET
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. Key Financial Highlights: Revenues for the year ended December 31, 2019 increased by 273%...
Apr 16, 2020 08:00 am ET
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the addition of eight new hospitals Endonovo’s SofPulse® medical device is approved for use. The eight hospitals are located in the following geographic areas:...
Mar 25, 2020 08:00 am ET
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces the intent to distribute of SofPulse® investigational units to Hospital Intensive Care Units across the United States to help mitigate severe respiratory...
Mar 16, 2020 08:00 am ET
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it will donate SofPulse® devices to Intensive Care Units and medical professionals for investigational use to evaluate SofPulse® PEMF technology’s inflammation...
Mar 02, 2020 07:30 am ET
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it has filed an 8K with the Securities and Exchange Commission (SEC) regarding a presentation on SofPulse® their companies flagship Electroceutical® device. The...
Feb 24, 2020 01:00 pm ET
Endonovo Therapeutics Introduces Support of SofPulse® With A New Ancillary Multi-Use Patient Brace From Protex
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the production and introduction of an ancillary multi-use patient brace designed to support all applications and uses of their PEMF SofPulse® units. The new...
Feb 20, 2020 11:00 am ET
Endonovo Therapeutics Begins Process For Medical Reimbursements
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced undertaking initial steps for obtaining medical reimbursements for their FDA-cleared SofPulse® device. Endonovo considers plans to pursue reimbursement for...
Feb 13, 2020 07:30 am ET
Endonovo Therapeutics Announces collaborating with a Stanford University sponsored Orthopedic Shoulder and Knee Study
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced Endonovo Therapeutics is collaborating with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo's tPEMF...
Feb 10, 2020 07:30 am ET
Endonovo Therapeutics announces its collaboration with Major Universities for the Evaluation of SofPulse® for Orthopedic Surgeries
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced their SofPulse® device is being evaluated at major universities for orthopedic surgeries. SofPulse® is Endonovo’s FDA-Cleared, non-invasive device utilized...
Feb 04, 2020 07:30 am ET
Endonovo Therapeutics Reduces Debt
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") is pleased to announce the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares....
Jan 30, 2020 07:00 am ET
Endonovo Therapeutics Expands SofPulse® Sales to Plastic Surgery Centers
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced sales of SofPulse® units to multiple Plastic Surgery Centers. SofPulse® is Endonovo’s FDA-Cleared, non-invasive device utilized for the reduction of...
Jan 27, 2020 07:00 am ET
Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced initial sales of SofPulse® units into a VA hospital in Texas. SofPulse® is Endonovo’s FDA-Cleared non-invasive device for reduction of postoperative pain and...
Jan 14, 2020 09:00 am ET
Endonovo Therapeutics Announces Issuance of Broad Patent Covering Electromagnetic Treatment of Multiple Sclerosis
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent for Application No. 15/549,748 covering method and apparatus for...
Jan 07, 2020 08:30 am ET
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke
Endonovo Therapeutics, Inc. (OTCQB: ENDVD / ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 15217855, which is directed to the usage of an Apparatus and...
Dec 23, 2019 08:30 am ET
Endonovo Therapeutics Provides SofPulse® To All NFL Teams
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all thirty-two National Football League (“NFL”) teams. Alan Collier, CEO of Endonovo Therapeutics stated,...
Dec 19, 2019 06:24 pm ET
Endonovo Therapeutics Announces Effective Date of Previously Announced Reverse Split of Common Stock
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today that its previously announced 1-for-1,000 reverse split of its common stock will become effective as of December 19, 2019. Beginning on December 20, 2019, the...
Dec 11, 2019 01:40 pm ET
Endonovo Therapeutics Announces Reverse Stock Split - UPDATE
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. The reverse stock split will take effect, and the...
Dec 11, 2019 12:48 pm ET
Endonovo Therapeutics Announces Reverse Stock Split
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company’s issued common shares. The reverse stock split will take effect, and the...
Nov 19, 2019 04:35 pm ET
Endonovo Therapeutics Reports Third Quarter 2019 Results
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30, 2019. Key Financial Highlights: Revenues for the three months ended September 30, 2019...
Oct 31, 2019 12:43 pm ET
Endonovo Therapeutics Announces Reverse Stock Split
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced that it had filed a preliminary information statement with respect to a proposed a reverse stock split of its common stock at a ratio of between 1 for 100 and...
Sep 30, 2019 09:00 am ET
Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces it has appointed Dr. William Li as Strategic Advisor to the CEO. Dr. Li and Endonovo CEO Alan Collier will work collaboratively and strategically to explore...
Sep 09, 2019 09:00 am ET
Endonovo Partners with Veterans Healthcare Supply Solutions, Appoints Samir Awad, M.D., to Scientific Advisory Board
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announces a partnership with Veterans Healthcare Supply Solutions to initiate SofPulse®...
Aug 30, 2019 09:00 am ET
Endonovo Therapeutics Appoints Dr. Geoffrey Abrams of Stanford University to Its Scientific Advisory Board
via NetworkWire -- Endonovo Therapeutics Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announces the appointment of orthopedic surgeon Dr. Geoffrey Abrams...
Aug 13, 2019 01:39 pm ET
Endonovo Therapeutics Announces Second Quarter Results
via NetworkWire – Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the second quarter ended June 30, 2019. Alan Collier, Endonovo’s chief executive officer, stated, “I...
Jul 22, 2019 12:40 pm ET
Endonovo Therapeutics Inc. Featured in Exclusive NetworkNewsWire Broadcast
via NetworkNewsAudio – Endonovo Therapeutics Inc. (OTCQB: ENDV), an innovative biotechnology company and commercial-stage developer of noninvasive Electroceutical™ therapeutic devices, today announces the broadcast of its exclusive audio interview...
Jul 15, 2019 08:30 am ET
Endonovo Therapeutics Appoints Dr. Peter Novak to its Scientific Advisory Board
via NetworkWire -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical™ therapeutic devices, today announces the appointment of Peter Novak, M.D., Ph.D., to its...
Jun 21, 2019 09:22 am ET
Endonovo Therapeutics Appoints Dr. Steven Levin of Johns Hopkins University to Its Scientific Advisory Board
via NetworkWire – Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announces the appointment of Steven Levin, M.D., to its scientific...
Jun 13, 2019 08:30 am ET
Endonovo Therapeutics Announces National Rollout of SofPulse® Post-Operative Opioid Alternative into Hospitals
via NetworkWire -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today its initial plans and strategy for a national rollout of...
May 29, 2019 08:30 am ET
Coverage Initiated for Endonovo Therapeutics via NetworkNewsWire
via NetworkWire -- Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, today announces it has selected the corporate communications expertise of NetworkNewsWire...
May 21, 2019 09:20 am ET
Endonovo Therapeutics and Veterans Healthcare Supply Solutions Announce Distribution Agreement
Endonovo Therapeutics, Inc. (OTCQB: ENDV) and Veterans Healthcare Supply Solutions Inc. (VHSS) today announced a long-term agreement encompassing the distribution of SofPulse® to Veterans Administration Facilities and Department of Defense...
May 09, 2019 09:20 am ET
Endonovo Therapeutics Appoints Dr. Roc Alan McCarthy as a Scientific Advisory Board Member
Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, that Roc Alan McCarthy, D.O. will be joining the company as a Scientific Advisory Board Member. Dr. McCarthy will help Endonovo continue to advance their clinical pipeline forward and...
May 07, 2019 09:20 am ET
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position, Mr. Ford will be responsible for growing Endonovo’s pipeline of marketing, content and thought...
May 03, 2019 09:20 am ET
Endonovo Therapeutics Hires David Clark as Vice President of Sales
Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new position, Mr. Clark will lead the U.S. Sales Team, distributors and strategic partners through the...
May 02, 2019 09:20 am ET
Endonovo Therapeutics Hires Nevena Zubcevik of Harvard Medical School as Chief Medical Officer
Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced the appointment of Nevena Zubcevik, DO, MSPT, ATC as its chief medical officer starting July 1, 2019. In her new role, Dr. Zubcevik will be in charge of medical and clinical strategy,...
Apr 26, 2019 08:00 am ET
Endonovo Therapeutics Provides Corporate Update
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced a corporate update and business plan for the remainder of 2019. Revenue...
Mar 29, 2019 08:00 am ET
Endonovo Therapeutics Announces Partnership with Second Hospital
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an agreement with a nationally recognized hospital group to enhance the quality of the healthcare/patient experience through the use of its electroceutical...
Mar 22, 2019 08:00 am ET
Endonovo Therapeutics Granted Trademarks for WoundPulse and OrthoHalo
March 22, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies brand, today announced the U.S. Patent and Trademark Office has awarded the company a...
Mar 20, 2019 08:00 am ET
Endonovo Therapeutics Partners with SunMED Medical Systems
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), Alan Collier, Endonovo’s Chief Executive Officer, stated "We are pleased to announce our partnership with SunMED Medical Solutions (“SunMED”). SunMED is one of the premier...
Feb 27, 2019 08:00 am ET
Endonovo Therapeutics Announces New Website Launch
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today the launch of its newly revamped website www.sofpulse.com. The website’s...
Feb 08, 2019 08:00 am ET
Endonovo Therapeutics Files Lawsuit against KVP International Inc., Orthocor Medical Inc., and Careus Corp. for Patent Infringement
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, filed a patent infringement lawsuit today in the U.S. District Court for the Central...
Jan 11, 2019 09:15 am ET
Endonovo Therapeutics Issues Shareholder Letter and Update
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced the issuance of the following shareholder letter from its Chief Executive...
Jan 03, 2019 11:10 am ET
Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today it has executed a Common Stock Purchase Agreement (the “Purchase Agreement”)...
Dec 18, 2018 09:25 am ET
Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies brand, today announced the allowance for the patent application entitled DEVICES AND METHOD FOR...
Dec 13, 2018 09:20 am ET
Endonovo Expands SofPulse Commercialization
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the commercialization and further advancement of its proprietary product – SofPulse®....
Dec 03, 2018 10:00 am ET
Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the company has entered into a non-binding Letter of Intent for a strategic...
Nov 08, 2018 10:00 am ET
Endonovo Therapeutics Announces Complimentary New Product
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the expansion of their suite of complimentary products with the ORTHOHALO™....
Oct 22, 2018 10:00 am ET
Endonovo Therapeutics Provides Update on Liver Study
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced results performed in a study to determine if Sofpulse® could counteract the effects of...
Aug 14, 2018 09:25 am ET
Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical™ System
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Magniant, LLC (“Magniant”) for the distribution of  SofPulse®, its...
Jun 14, 2018 08:30 am ET
Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced that the first patient has been enrolled in a clinical study at the University of New Mexico Health...
May 09, 2018 01:30 pm ET
Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical™ SofPulse®
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Plagens Medical Consultants for the distribution of  SofPulse™, its...
May 01, 2018 07:35 am ET
Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
Company to Conduct Larger Clinical Study to Evaluate Its Electroceutical™ Therapy in Chronic Kidney Disease
Apr 18, 2018 10:00 am ET
Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico
Los Angeles, CA, April 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced an agreement to commence a clinical research study entitled Pulsed Electromagnetic...
Feb 12, 2018 09:32 am ET
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
LOS ANGELES, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of critical limb ischemia (CLI) in...
Feb 01, 2018 09:32 am ET
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics™ Reduced Infarct Size and Inhibited Fibrosis following Myocardial Infarction
LOS ANGELES, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of post-myocardial infarction remodeling in mice.
Jan 22, 2018 07:00 am ET
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
Seeking Distribution Partners in Europe for CE-Marked Electroceutical™ Device for Promotion of Wound Healing, Reduction of Pain and Post-Operative Edema
Jan 16, 2018 09:35 am ET
Endonovo Therapeutics Provides Corporate Update and 2018 Outlook
- Announces Series C Preferred Stock Offering 
Jan 11, 2018 09:00 am ET
Endonovo Therapeutics Engages ShareIntel, A Leader In Shareholder Intelligence Services To Investigate Market Maker and Clearing Firm Irregularities
LOS ANGELES, CA, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a clinical-stage developer of non-invasive electroceuticals for the treatment of central nervous system (CNS) disorders, today announced it is working with...
Dec 28, 2017 09:30 am ET
Endonovo Therapeutics Provides Update on Acquisition of PEMF Assets, Clinical Pipeline and Pre-Clinical Study
LOS ANGELES, CA, Dec. 28, 2017 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a clinical-stage developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today provided an update on the...
Dec 26, 2017 07:30 am ET
Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit
Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders
Oct 13, 2017 07:30 am ET
Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today reported that it has completed a study to evaluate the potential efficacy of its Immunotronics™ platform, a non-invasive electroceutical, in a well-established preclinical model of heart failure (post-MI remodeling). With these positive results, the Company continues to advance the development of its pipeline of non-invasive electroceuticals targeting vascular diseases and inflammatory conditions
Sep 26, 2017 02:15 pm ET
Endonovo Therapeutics Provides Update on Pre-Clinical Studies
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today provided an update on its pre-clinical studies and interim results from its pre-clinical study to assess the effectiveness of its Immunotronics™ platform in the treatment and prevention of heart failure following myocardial infarction.
Sep 22, 2017 01:08 pm ET
Endonovo Therapeutics, Inc. and Kodiak Capital Group, LLC Announce Settlement and Dismissal of Lawsuit
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, and Kodiak Capital Group, LLC ("Kodiak"), a private equity firm, today announced a settlement agreement and dismissal of complaints and cross-complaints arising out of a contemplated equity investment by Kodiak in Endonovo.
Jun 29, 2017 08:30 am ET
Endonovo Therapeutics Issues Open Letter and Update to Its Shareholders
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today issued an open letter to shareholders.
Jun 01, 2017 08:00 am ET
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Kidney Disease
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease. The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute
May 11, 2017 09:00 am ET
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation in Non-Alcoholic Steatohepatitis (NASH). The study is the first of several currently planned studies targeting inflammatory pathologies of hepatic origin.
May 04, 2017 12:51 pm ET
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device for Treatment of Critical Limb Ischemia
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the treatment of critical limb ischemia (CLI). The pre-clinical study will evaluate the effect of the Company's non-invasive electroceutical technology on limb function, ischemia damage and blood flow, including the formation of new blood vessels
Mar 23, 2017 09:29 am ET
Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in tissues and organs, today announced that it has filed a non-provisional patent application with the United States Patent and Trademark Office (USPTO) covering a method to treat tissues and organs using its non-invasive electroceutical technology.
Dec 19, 2016 09:00 am ET
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the prevention of heart failure following myocardial infarction (MI). The pre-clinical study will evaluate the effect of the Company's non-invasive electroceutical technology on cardiac function, post-MI remodeling, and infarct size, as well as
Nov 28, 2016 12:29 pm ET
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing to redeem all of its outstanding convertible notes, fund several pre-clinical studies targeting vascular diseases and ischemic injuries in vital organs and to prepare to uplist the Company's common stock onto a national stock exchange.
Nov 21, 2016 09:21 am ET
Endonovo (ENDV) Benefits from NASH Buying Spree -- SECFilings.com
SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing efforts to develop the first FDA-approved treatment for Non-alcoholic Steatohepatitis (NASH). Many companies are in the hunt, and Endonovo Therapeutics (OTCQB: ENDV) is taking a unique approach with its Immunotronics™ electroceutical platform.
Nov 14, 2016 09:00 am ET
How New Technologies Could Revolutionize Drug Discovery -- SECFilings.com
SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing several new technologies that may decrease the prohibitive costs typically associated with drug discovery. Included in the report is Endonovo Therapeutics (OTCQB: ENDV) and its Cytotronics™ drug development platform based on bioelectronics technology.
Nov 07, 2016 09:05 am ET
Endonovo Therapeutics (ENDV): Targeting $20+ Billion Market for In Vitro ADME and Toxicology Testing
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and non-invasive electroceuticals for the treatment of inflammatory conditions in vital organs, today announced that it is expanding its liver disease research program and its Cytotronics™ platform to create a high-fidelity drug development and toxicology testing platform.
Oct 28, 2016 08:30 am ET
The Non-Invasive Advantage of Endonovo Therapeutics' (OTCQB: ENDV) Electroceuticals -- SECFilings.com
SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the role Endonovo Therapeutics Inc. (OTCQB: ENDV) plays in the emerging multi-billion dollar electroceutical industry.
Oct 18, 2016 08:57 am ET
SECFilings Releases Report on Why Bioelectronics are the Future of Medicine
SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published a report on the emerging bioelectronic medicine industry. In the report, the differences between pulsed electromagnetic fields (PEMF) and surgical implants are discussed, along with companies that have become innovators in both sides of the industry. Companies discussed in the report include Endonovo Therapeutics Inc. (OTCQB: ENDV), GlaxoSmithKline plc, and Alphabet Inc.'s Verily Life Science LLC.
Oct 18, 2016 07:05 am ET
Endonovo Therapeutics Announces Registration Statement on Form S-1 has been Declared Effective
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and non-invasive electroceuticals for the treatment of inflammatory conditions in vital organs, today announced that the Securities and Exchange Commission ("SEC") has declared effective the Company's registration statement on Form S-1 relating to the resale of up to 16,676,057 shares of the Company's common stock, par value of $0.0001 per share (the "Common Shares") held by or that may be acquired by certain securityholders of the Company named in the registration statement.
Oct 14, 2016 06:50 am ET
Endonovo Therapeutics Issues Corporate Update
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive electroceuticals for the treatment of inflammatory conditions in vital organs, today provided a corporate update and announced its plan to uplist its common stock onto a national stock exchange.
Oct 07, 2016 08:30 am ET
SECFilings Releases Report on Biotech Companies Targeting Liver Disease
SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published a report on Non-Alcoholic Steatohepatitis -- a silent epidemic that is destroying the liver of tens of millions of Americans. In the report, there's a discussion of the biotech companies that are actively targeting the space, both large and small.
Sep 29, 2016 08:58 am ET
Endonovo at the Intersection of Stem Cells and Biologics for Next Generation Therapeutics - SECFilings.com
SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article covering the unique technology that Endonovo Therapeutics (OTCQB: ENDV) is applying in the development of biologics and stem cells.
Sep 15, 2016 09:13 am ET
Endonovo Establishing Its Footprint in Non-Invasive Bioelectronic Medicine Space -- SECFilings.com
SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering Endonovo Therapeutics' (OTCQB: ENDV) novel, non-invasive and NASA-developed bioelectronics technology. Also included is an executive interview with Endonovo CEO Alan Collier.
Aug 19, 2016 06:00 pm ET
Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that the binding letter agreement (LOI) to acquire Rio Grande Neurosciences (RGN), announced on July 11, 2016, has been dissolved effective today. The Company will not be proceeding with the acquisition.
Aug 10, 2016 08:05 am ET
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that it has filed a patent titled, "Methods and Compositions for Treating Chemical and Radiation Injuries." The patent filing covers the production of biologics, including cell therapies and biomolecules created using a proprietary bioreactor and their corresponding administration as a therapeutic for treating chemical and radiation injuries, including chemotherapy and radiation exposure.
Aug 09, 2016 07:00 am ET
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,410,143 covering the use of electromagnetic stimulation of cells to produce biological molecules. This newly-issued patent covers the production of human biomolecules commonly used as biologics, including EPO, G-CSF, GM-CSF, and IL-2.
Jul 15, 2016 11:20 am ET
Endonovo Therapeutics Announces New Round of Financing
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and medicines, announced today that it has entered into a funding agreement with an institutional investor to provide up to an aggregate of $10 million in financing consisting of (a) $1 million in Convertible Notes (the "Notes"), of which $400,000 has been received to date, and (b) up to $9 million in financing through a Securities Purchase Agreement (the "SPA").
Jul 11, 2016 06:15 am ET
Endonovo Therapeutics Announces Binding Letter of Intent to Acquire Rio Grande Neurosciences, Inc.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a developer of bioelectronic devices and medicines, announced today it has executed a binding letter of intent (LOI) to acquire Rio Grande Neurosciences, Inc. (RGN), a privately-held clinical stage developer of non-invasive Electroceuticals™ for the treatment of neuro-inflammation and central nervous system diseases and disorders. The LOI is binding, but subject to the execution of a definitive purchase agreement, shareholder approvals from both companies and Endonovo raising additional capital. The parties expect to sign a definitive
Jun 29, 2016 09:32 am ET
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Endonovo's patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully human biologic.
Jun 23, 2016 05:02 am ET
Endonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et al
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic medicine and therapies, announced it has been awarded a preliminary injunction by the Superior Court of California, County of Los Angeles, against Kodiak Capital, BMA Securities and COR Clearing, preventing the aforementioned parties from selling, transferring, hypothecating or otherwise touching or disposing of unpaid for shares tendered under the Equity Purchase Agreement (the "EPA") with Kodiak Capital. The preliminary injunction affirms a previously granted temporary restraining order
Jun 15, 2016 09:07 am ET
Endonovo Therapeutics Provides Update on Variable Convertible Notes
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic medicine and therapies, announced it has retired two variable conversion rate notes for $55,000 and $50,750 respectively, which the Company believes sets the stage for a new financing plan. Additionally, the Company announced it has received a temporary restraining order against Kodiak Capital, COR Clearing and BMA Securities barring their ability to trade, lend or hypothecate all the remaining shares under the Equity Purchase Agreement with Kodiak Capital, including 1.89 million freely
May 31, 2016 07:49 pm ET
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
NEW YORK, May 31, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York.  The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community.  The Conference will feature presentations by CEOs and CFOs from various industr
May 05, 2016 02:45 pm ET
Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company overview at the 2016 Marcum Microcap Conference on June 2, 2016. The event will be held at the Grand Hyatt New York on Park Avenue at Grand Central.
Apr 13, 2016 08:34 am ET
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City.
Mar 30, 2016 03:12 pm ET
Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells."
Mar 14, 2016 03:09 pm ET
Endonovo Therapeutics Provides Corporate Update and 2016 Outlook
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today a number of corporate developments.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.